Highlights NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

End-of-day quote Korea S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
1,770 ^KRW	-4.48%		-7.28%	-12.59%

02/04	NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	CI
15/01	NeoImmuneTech, Inc. Appoints Luke Oh as President	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome	20/11	CI
NeoImmuneTech, Inc. to Partner with U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health for Drug Development in Acute Radiation Syndrome	03/23/03	CI
New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors	11/22/11	CI
NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity	15/22/15	CI
NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors	06/22/06	CI
Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022	13/22/13	CI
NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers	07/22/07	CI
NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7	24/22/24	CI
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	28/21/28	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	25/21/25	CI
NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting	22/21/22	CI
NeoImmuneTech, Inc. Presents Data in Three Posters At Society for Immunotherapy of Cancer Annual Meeting	16/21/16	CI
NeoimmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (Efineptakin Alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer	08/21/08	CI
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma	13/21/13	CI
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting	04/21/04	CI
Neoimmunetech to Present At Society for Neuro-Oncology	13/21/13	CI
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection	26/21/26	CI
NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo®	08/21/08	CI
NeoImmuneTech, Inc. Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy	24/21/24	CI
NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors	23/21/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

Highlights

Filters